October 10, 2022 – UGGC Avocats, one of France’s leading independent law firms and a multidisciplinary business law firm, has supported Tridek-One, a biotech start-up specialized in the research and development of CD31 agonists to restore immune balance, in its €16 million capital raising from new investors Pureos BioVentures, Bpifrance through its InnoBio2 fund, Bioqube Ventures and existing investors AdBio Partners, Advent Life Sciences.
Founded in 2018 by Dr. Giuseppina Caligiuri and Prof. Antonino Nicoletti, researchers at INSERM Unit 1148 (Paris), the start-up is developing a CD31 agonist approach designed to modulate immune activation for the treatment of autoimmune diseases.
Tridek-One had, in 2019, previously raised €3 million.
The UGGC Avocats team assisting Tridek-One is composed of Charles-Emmanuel Prieur, partner, Rebecca El Hakim, associate and Laurie-Durand, associate.